New keytruda copycat tested in melanoma trial
NCT ID NCT06551064
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether FYB206, a biosimilar (or copycat) of the cancer drug Keytruda, works similarly in the body. It involves 96 people with stage IIB/IIC or III melanoma that was completely removed by surgery. Participants receive either FYB206 or Keytruda, and researchers compare how the drug levels behave over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FYB206 (a biosimilar to pembrolizumab/Keytruda)
What this could lead to
If successful, FYB206 could offer a more affordable alternative to Keytruda for preventing melanoma recurrence after surgery.
What could go wrong
This is an early phase 1 trial focused on drug levels in the body, not yet on effectiveness. Biosimilars may not perform identically, and results may not guarantee long-term benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA STAGE III are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Formycon Investigative Site
Sarajevo, Bosnia and Herzegovina
-
Formycon Investigative Site
Sofia, Bulgaria
-
Formycon Investigative Site
Tartu, Estonia
-
Formycon Investigative Site
Batumi, Georgia
-
Formycon Investigative Site
Kutaisi, Georgia
-
Formycon Investigative Site
Tbilisi, Georgia
-
Formycon Investigative Site
Kaunas, Lithuania
-
Formycon Investigative Site
Chisinau, Moldova
-
Formycon Investigative Site
Skopje, North Macedonia
-
Formycon Investigative Site
Krakow, Poland
-
Formycon Investigative Site
Lodz, Poland
-
Formycon Investigative Site
Bucharest, Romania
-
Formycon Investigative Site
Cluj-Napoca, Romania
-
Formycon Investigative Site
Belgrade, Serbia
-
Formycon Investigative Site
Kragujevac, Serbia
-
Formycon Investigative Site
Niš, Serbia
-
Formycon Investigative Site
Kyiv, Ukraine